The rapid progress in CRISPR gene editing technology has presented a promising future for the treatment of various diseases. Following the approval of the first CRISPR-based therapeutic, Casgevy, in several countries, including the UK and the US, there has been an uptick in research and development of gene editing therapies. However, the high cost of these treatments, typically ranging from $200,000 to over $300,000, poses a significant barrier to access. Furthermore, the complex nature of gene editing technologies, including CRISPR-Cas9, and the potential off-target effects, have sparked concerns about safety and efficacy. Despite these challenges, scientists are working to improve the precision and efficiency of gene editing technologies, such as CRISPR-Cas9, and develop new methods, like base editing and prime editing. These advances are crucial for making gene editing therapies more accessible and safer for patients. As researchers continue to refine and perfect gene editing technologies, the potential for breakthroughs in the field is vast, and there is hope for a future where gene editing therapies are a viable option for treating a wide range of diseases.